Table 1.
Biologic treatment options to treat psoriasis.
| Biologic drug | Target cytokine | Cardiovascular effects |
|---|---|---|
| Etanercept | Tumor necrosis factor-α | Observational data indicating better CV outcomes. RCT for subclinical cardiovascular disease (CVD) demonstrating promising results. RCT dedicated for CV events not available (139, 140, 143) |
| Infliximab | ||
| Adalimumab | ||
| Secukinumab | Interleukin-17A and interleukin-17A receptor for brodalumab | Dedicated RCT for CV events unavailable |
| Ixekizumab | ||
| Bimekizumab | ||
| Brodalumaba | ||
| Ustekinumab | Interleukin-12/23p40 | RCT for subclinical CVD demonstrating favorable results. Dedicated RCT unavailable (144) |
| Briakinumaba | ||
| Guselkumab | Interleukin-23p19 | No data available yet for CV effects |
| Tildrakizumab | ||
| Risankizumab | ||
| Fezakinumab | Interleukin-22 | Drug still in early development phase |
aDiscontinued medications from the market.